title: Incorporation of pazopanib in maintenance therapy of ovarian cancer.
abstract: OBJECTIVE
  Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -1/-2/-3, platelet-derived growth factor receptor (PDGFR) -α/-β, and c-Kit. Preclinical and clinical studies support VEGFR and PDGFR as targets for advanced ovarian cancer treatment. This study evaluated the role of pazopanib maintenance therapy in patients with ovarian cancer whose disease did not progress during first-line chemotherapy.
  
  
  METHODS
  Nine hundred forty patients with histologically confirmed cancer of the ovary, fallopian tube, or peritoneum, International Federation Gynecology Obstetrics (FIGO) stages II-IV, no evidence of progression after primary therapy consisting of surgery and at least five cycles of platinum-taxane chemotherapy were randomized 1:1 to receive pazopanib 800 mg once per day or placebo for up to 24 months. The primary end point was progression-free survival by RECIST 1.0 assessed by the investigators.
  
  
  RESULTS
  Maintenance pazopanib prolonged progression-free survival compared with placebo (hazard ratio [HR], 0.77; 95% CI, 0.64 to 0.91; P = .0021; median, 17.9 v 12.3 months, respectively). Interim survival analysis based on events in 35.6% of the population did not show any significant difference. Grade 3 or 4 adverse events of hypertension (30.8%), neutropenia (9.9%), liver-related toxicity (9.4%), diarrhea (8.2%), fatigue (2.7%), thrombocytopenia (2.5%), and palmar-plantar erythrodysesthesia (1.9%) were significantly higher in the pazopanib arm. Treatment discontinuation related to adverse events was higher among patients treated with pazopanib (33.3%) compared with placebo (5.6%).
  
  
  CONCLUSIONS
  Pazopanib maintenance therapy provided a median improvement of 5.6 months (HR, 0.77) in progression-free survival in patients with advanced ovarian cancer who have not progressed after first-line chemotherapy. Overall survival data to this point did not suggest any benefit. Additional analysis should help to identify subgroups of patients in whom improved efficacy may balance toxicity (NCT00866697).
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Andreas
authors.initials: A
authors.lastname: du Bois
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Anne
authors.initials: A
authors.lastname: Floquet
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Jae-Weon
authors.initials: JW
authors.lastname: Kim
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Joern
authors.initials: J
authors.lastname: Rau
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Josep M
authors.initials: JM
authors.lastname: del Campo
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Michael
authors.initials: M
authors.lastname: Friedlander
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Sandro
authors.initials: S
authors.lastname: Pignata
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Keiichi
authors.initials: K
authors.lastname: Fujiwara
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Ignace
authors.initials: I
authors.lastname: Vergote
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Colombo
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Mansoor R
authors.initials: MR
authors.lastname: Mirza
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Bradley J
authors.initials: BJ
authors.lastname: Monk
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Rainer
authors.initials: R
authors.lastname: Kimmig
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Isabelle
authors.initials: I
authors.lastname: Ray-Coquard
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Rongyu
authors.initials: R
authors.lastname: Zang
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Ivan
authors.initials: I
authors.lastname: Diaz-Padilla
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Klaus H
authors.initials: KH
authors.lastname: Baumann
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Marie-Ange
authors.initials: MA
authors.lastname: Mouret-Reynier
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Jae-Hoon
authors.initials: JH
authors.lastname: Kim
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Christian
authors.initials: C
authors.lastname: Kurzeder
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Anne
authors.initials: A
authors.lastname: Lesoin
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Paul
authors.initials: P
authors.lastname: Vasey
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Christian
authors.initials: C
authors.lastname: Marth
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Ulrich
authors.initials: U
authors.lastname: Canzler
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Giovanni
authors.initials: G
authors.lastname: Scambia
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Muneaki
authors.initials: M
authors.lastname: Shimada
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Paula
authors.initials: P
authors.lastname: Calvert
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Eric
authors.initials: E
authors.lastname: Pujade-Lauraine
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Byoung-Gie
authors.initials: BG
authors.lastname: Kim
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Herzog
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Ionel
authors.initials: I
authors.lastname: Mitrica
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Carmen
authors.initials: C
authors.lastname: Schade-Brittinger
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Qiong
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Rocco
authors.initials: R
authors.lastname: Crescenzo
authors.affiliation: Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan
authors.forename: Philipp
authors.initials: P
authors.lastname: Harter
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007191:Indazoles; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib; D040262:Receptors, Vascular Endothelial Growth Factor